SFDA Acceptance of FDA Approvals: What You Need to Know

Key Takeaways

• Fast-track timelines: SFDA verification pathway targets 30 working days for dual FDA/EMA approved products; abridged pathway targets 60 working days for single reference agency approval (SFDA Guidance v3.0).
• Product scope: Pathways cover new chemical entities (NCEs) and biological products; applications must be filed within two years of reference agency approval (SFDA Regulatory Framework).
• GMP inspection waivers: Manufacturing sites with valid FDA, EMA, or GCC-DR GMP certificates may qualify for inspection waivers, reducing time-to-market.
• Regional harmonization: The GCC-DR framework complements SFDA pathways, enabling multi-country regulatory coordination across Gulf states.
• Exclusions apply: Blood products, advanced therapy medicinal products, and veterinary vaccines are not eligible for reliance pathways.

What Are SFDA Reliance Pathways?

The SFDA uses reliance-based regulatory pathways. These recognize prior scientific reviews from stringent regulatory authorities (SRAs) including the FDA and EMA. This aligns with WHO principles on regulatory reliance.

The SFDA does not duplicate full scientific reviews. Instead, it builds on existing benefit-risk evaluations from reference agencies. The SFDA focuses on Saudi-specific factors: Good Manufacturing Practice (GMP) compliance, Arabic labeling, stability data under Gulf climate conditions, and local disease patterns.

How Does the Verification Pathway Work?

The verification pathway applies to new human and veterinary medicines that have received approval from both the FDA and EMA. Products must be marketed in the reference agencies' jurisdictions.

Applicants must submit complete, unredacted assessment reports from both regulatory agencies. These reports must include chemistry, clinical, and quality reviews. The SFDA requires documentation of any post-approval variations (SFDA Verification & Abridged Pathways v3.0).

The performance target for verification pathway reviews is 30 working days. This timeline begins after the Drug Sector approves the pathway designation via email. The clock stops if the SFDA requests clarification from the applicant.

How Does the Abridged Pathway Work?

The abridged pathway serves products approved by either the FDA or EMA—not both. This pathway provides flexibility for products with one major reference agency approval.

Documentation mirrors the verification pathway but requires reports from only one agency. The SFDA targets 60 working days for abridged reviews. SFDA guidance v3.0, effective January 2026, expanded this pathway to include Type II variation applications for post-approval changes.

What Are the Eligibility Requirements?

Products must meet several criteria to qualify for reliance pathways:

• Product type must be a new chemical entity (NCE) or biological product; generics are excluded unless first-in-class
• Application must be submitted within two years from the reference agency's approval date
• Product must not have been rejected, withdrawn, or suspended for safety or efficacy reasons
• Product must not need more stringent assessment due to local disease patterns in Saudi Arabia
• Manufacturing site, formulation, release specs, and API source must match the reference agency's approved configuration

Excluded categories include blood products, advanced therapy medicinal products (ATMPs), and veterinary vaccines. The SFDA requires a pre-designation meeting to confirm eligibility (SFDA Regulatory Framework v6.4).

What Documentation Does SFDA Require?

Applicants must submit an eCTD (electronic Common Technical Document) dossier with specific Module 1 requirements:

1. Cover letter specifying the pathway and reference agency approval dates
2. Declaration letter confirming all quality aspects match the reference agency's approved configuration
3. Complete assessment reports from reference agencies (unredacted and unedited)
4. Valid GMP certificates from local and international authorities
5. Site Master File (SMF) for manufacturing facilities
6. Last inspection report from the local authority

The SFDA accepts minor changes to container closure systems (for example, Alu/Alu blister versus HDPE bottle) to meet GCC stability requirements. However, the core formulation and manufacturing process must match the reference-approved product.

When Does SFDA Waive GMP Inspections?

GMP inspections may be waived for sites certified by FDA, EMA, or GCC-DR. The waiver applies when the applicant submits:

• Valid GMP certificates from local and international authorities
• Complete Site Master File (SMF)
• List of all products manufactured at the site for Saudi Arabia
• Last inspection report in English from the local authority

If the site is in a country eligible under SFDA criteria, inspection will not block registration. The SFDA commits to maintaining timelines even when inspections are required (SFDA Guidance).

How Do Reliance Pathways Compare to Standard Registration?

Standard SFDA registration typically requires 9 to 12 months for new molecules. The verification pathway reduces this to about 30 working days. The abridged pathway targets 60 working days.

SFDA Registration Pathway Comparison

Pathway	Review Timeline	Reference Agency	Product Types
Verification	30 working days	FDA and EMA	NCEs, biologics
Abridged	60 working days	FDA or EMA	NCEs, biologics
Priority Review	40% reduction from standard	Any	Serious conditions, unmet medical needs
Standard	9-12 months	None required	All eligible products

What Happens If SFDA Identifies Safety Concerns?

Approval by reference agencies does not guarantee SFDA approval. The SFDA retains full regulatory authority over all decisions. During evaluation, SFDA departments may transfer applications to the regular pathway if safety, efficacy, or quality concerns emerge.

The SFDA commits to clarifying decisions for any transferred case. If the application moves to the standard pathway, registration fees are not refundable. Companies may appeal SFDA decisions within 60 calendar days of notification.

How Do GCC-DR and SFDA Pathways Interact?

The Gulf Central Committee for Drug Registration (GCC-DR) runs a centralized registration procedure across GCC states. Products approved through GCC-DR may receive fast-track consideration in Saudi Arabia.

Products registered in two or more GCC states can receive a centralized certificate through the GCC Health Council. The SFDA accepts GCC-DR approvals as part of its broader reliance framework. This coordination lets companies launch across Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE.

What Other Expedited Programs Does SFDA Offer?

Beyond reliance pathways, the SFDA maintains several fast-track programs:

• Priority Review: Introduced in 2014, cuts assessment timelines by about 40% for innovative drugs with serious conditions
• Breakthrough Medicines Program: Launched October 2023, speeds evaluation of innovative therapies with strong early data
• Conditional Approval: Allows temporary authorization for promising new medicines with incomplete data, requiring post-approval commitments
• Orphan Drug Designation: Provides incentives for rare disease therapies

The SFDA expedited review frameworks show Saudi Arabia's commitment to patient access while keeping safety standards.

Frequently Asked Questions

Primary Sources

1. Saudi Food and Drug Authority. Verification & Abridged Pathways Guideline Version 3.0. October 2025; effective January 2026.
2. Saudi Food and Drug Authority. Regulatory Framework for Drug Approvals Version 6.4. June 2024.
3. Saudi Food and Drug Authority. Verification & Abridged Process Guideline Version 2.2. May 2024.
4. World Health Organization. Regulation and Prequalification. Accessed July 2026.
5. Al-Rashidi H, et al. Advances in Regulatory Review Pathways in the Middle East. Thieme. 2025. doi:10.1055/s-0046-1820420.